Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Progression-free survival longer for brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus ABVD.
Among patients with cHL, mortality risk related to cancer has declined, but CVD mortality risk has decreased slowly or remained stable.
The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
The median overall survival was not reached at 3 years.
Researchers sought to investigate the associations between PTSS and the experiences of pediatric survivors of Hodgkin lymphoma treated in the AHOD0031 study.
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.
Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.